Literature DB >> 8392594

Involvement of membrane-bound viral glycoproteins in adhesion of pseudorabies virus-infected cells.

F P Hanssens1, H J Nauwynck, M B Pensaert.   

Abstract

Cell-associated spread of pseudorabies virus (PrV) plays an important role in the pathogenesis of the disease. Besides the already known direct cell-to-cell spread of the virus in monolayers, adhesion and subsequent fusion of suspended PrV infected cells to monolayers of uninfected cells are thought to occur. To study the adhesion of PrV-infected cells, an in vitro model was developed in SK-6 cells. Specific adhesion of PrV-infected cells to an uninfected monolayer started 5 h after infection of the cells and reached a maximum 6 h later. A correlation was found between the surface expression of PrV glycoproteins on the infected cells and the adhesion of these cells. PrV hyperimmune serum completely inhibited binding of the infected cells. To investigate which PrV envelope glycoproteins were responsible for the cell adhesion, the infected cells were incubated with antisera against glycoproteins gII, gIII, and gp50. Antiserum against either gII or gIII inhibited cell adhesion, and antisera against gII and gIII together had a cooperative effect. Antiserum against gp50 had no effect on binding when used alone but enhanced the inhibition induced by gII and gIII antisera. Heparin and neomycin inhibited adhesion, showing that the receptor for adhesion was a heparinlike substance. SK-6 cells infected with a gIII deletion mutant of PrV exhibited a much lower adhesion. This binding was heparin and neomycin independent and was not blocked by anti-gII serum. Nevertheless, it was completely inhibited with PrV hyperimmune serum and with anti-gp50 serum. This finding demonstrates that the ligand for adhesion of gIII(-)-infected cells is glycoprotein gp50. These results strongly suggest that the mechanism for adhesion of a PrV-infected cell to an uninfected monolayer is similar to the mechanism of adsorption and penetration of a PrV virion to a host cell.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8392594      PMCID: PMC237832     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Evidence that neomycin inhibits binding of herpes simplex virus type 1 to the cellular receptor.

Authors:  N Langeland; H Holmsen; J R Lillehaug; L Haarr
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

2.  Identification of antigenic sites on pseudorabies virus glycoprotein gp50 implicated in virus penetration of the host cell.

Authors:  M Eloit; H Bouzghaia; B Toma
Journal:  J Gen Virol       Date:  1990-09       Impact factor: 3.891

3.  Herpes simplex virus glycoprotein D is sufficient to induce spontaneous pH-independent fusion in a cell line that constitutively expresses the glycoprotein.

Authors:  G Campadelli-Fiume; E Avitabile; S Fini; D Stirpe; M Arsenakis; B Roizman
Journal:  Virology       Date:  1988-10       Impact factor: 3.616

4.  Role of glycoprotein B of herpes simplex virus type 1 in viral entry and cell fusion.

Authors:  W H Cai; B Gu; S Person
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

5.  Interaction of glycoprotein gIII with a cellular heparinlike substance mediates adsorption of pseudorabies virus.

Authors:  T C Mettenleiter; L Zsak; F Zuckermann; N Sugg; H Kern; T Ben-Porat
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

6.  Comparison of heparin-sensitive attachment of pseudorabies virus (PRV) and herpes simplex virus type 1 and identification of heparin-binding PRV glycoproteins.

Authors:  D Sawitzky; H Hampl; K O Habermehl
Journal:  J Gen Virol       Date:  1990-05       Impact factor: 3.891

7.  Vaccination against pseudorabies with glycoprotein gI+ or glycoprotein gI- vaccine.

Authors:  J Vandeputte; G Chappuis; D Fargeaud; P Précausta; F Guillemin; A Brun; P Desmettre; C Stellmann
Journal:  Am J Vet Res       Date:  1990-07       Impact factor: 1.156

8.  Early interactions of pseudorabies virus with host cells: functions of glycoprotein gIII.

Authors:  F Zuckermann; L Zsak; L Reilly; N Sugg; T Ben-Porat
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

9.  Pseudorabies virus glycoproteins gII and gp50 are essential for virus penetration.

Authors:  I Rauh; T C Mettenleiter
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

10.  A herpes simplex virus mutant in which glycoprotein D sequences are replaced by beta-galactosidase sequences binds to but is unable to penetrate into cells.

Authors:  M W Ligas; D C Johnson
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

View more
  6 in total

1.  Antibody-induced and cytoskeleton-mediated redistribution and shedding of viral glycoproteins, expressed on pseudorabies virus-infected cells.

Authors:  H W Favoreel; H J Nauwynck; P Van Oostveldt; T C Mettenleiter; M B Pensaert
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Adaptability in herpesviruses: glycoprotein D-independent infectivity of pseudorabies virus.

Authors:  J Schmidt; B G Klupp; A Karger; T C Mettenleiter
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

3.  Comparisons of the F and HN gene sequences of different strains of bovine parainfluenza virus type 3: relationship to phenotype and pathogenicity.

Authors:  M M Breker-Klassen; D Yoo; L A Babiuk
Journal:  Can J Vet Res       Date:  1996-07       Impact factor: 1.310

4.  Role of glycoprotein gD in the adhesion of pseudorabies virus infected cells and subsequent cell-associated virus spread.

Authors:  F P Hanssens; H J Nauwynck; T C Mettenlieter
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

5.  Effect of specific antibodies on the cell-associated spread of pseudorabies virus in monolayers of different cell types.

Authors:  H J Nauwynck; M B Pensaert
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

6.  Cell surface proteoglycans are not essential for infection by pseudorabies virus.

Authors:  A Karger; A Saalmüller; F Tufaro; B W Banfield; T C Mettenleiter
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.